ES2911678T3 - Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma - Google Patents

Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma Download PDF

Info

Publication number
ES2911678T3
ES2911678T3 ES16865176T ES16865176T ES2911678T3 ES 2911678 T3 ES2911678 T3 ES 2911678T3 ES 16865176 T ES16865176 T ES 16865176T ES 16865176 T ES16865176 T ES 16865176T ES 2911678 T3 ES2911678 T3 ES 2911678T3
Authority
ES
Spain
Prior art keywords
cancer
crystalline form
approximately
ray powder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16865176T
Other languages
English (en)
Spanish (es)
Inventor
Ning Xi
Mingming Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Application granted granted Critical
Publication of ES2911678T3 publication Critical patent/ES2911678T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES16865176T 2015-11-14 2016-11-12 Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma Active ES2911678T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255391P 2015-11-14 2015-11-14
PCT/US2016/061717 WO2017083788A1 (en) 2015-11-14 2016-11-12 Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ES2911678T3 true ES2911678T3 (es) 2022-05-20

Family

ID=58695598

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16865176T Active ES2911678T3 (es) 2015-11-14 2016-11-12 Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma

Country Status (5)

Country Link
US (1) US9920033B2 (enExample)
EP (1) EP3373932B1 (enExample)
JP (1) JP6921818B2 (enExample)
ES (1) ES2911678T3 (enExample)
WO (1) WO2017083788A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
EP3397618B1 (en) * 2015-12-30 2020-11-18 Synthon B.V. Process for making crystalline form a of gefitinib
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
EP3597636A4 (en) * 2017-03-14 2020-10-21 Allgenesis Biotherapeutics Inc. CRYSTALLINE FORMS OF 3-Z- [1- (4- (N - ((4-METHYL-PIPERAZIN-1-YL) -METHYLCARBONYL) -N-METHYL-AMINO) -PHENYLAMINO) -1-PHENYL-METHYLENE] -6 -METHOXYCARBONYL-2-INDOLINONE
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN113512006B (zh) * 2021-04-30 2025-01-28 瑞阳制药股份有限公司 达可替尼一水合物的晶型及其制备方法
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
MX2010012290A (es) * 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
MY181439A (en) 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
JP2018533608A (ja) 2018-11-15
EP3373932A1 (en) 2018-09-19
WO2017083788A1 (en) 2017-05-18
JP6921818B2 (ja) 2021-08-18
EP3373932A4 (en) 2019-08-07
US9920033B2 (en) 2018-03-20
US20170313678A1 (en) 2017-11-02
EP3373932B1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
ES2911678T3 (es) Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma
US9695150B2 (en) Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
ES2841600T3 (es) Sal de di(ácido metanosulfónico) de (3-cloro-4-fluoro-fenil)-(6-((4aR,7aS)-3-(hexahidro-(1,4)dioxino(2,3-c)pirrol-6-il)- propoxi)-7-metoxi-quinazolin-4-il)-amina y forma cristalina del monohidrato (un inhibidor de EGFR)
WO2022043865A1 (en) Crystalline form of heterobicyclic compound
WO2024149214A1 (en) Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024045066A1 (en) Alkylidene carbamate as kras inhibitors
ES2718557T3 (es) Nuevos compuestos como inhibidores de nik
JP2021509680A (ja) Ｇ１ｔ３８の優れた投与レジメン
CN108148071B (zh) 氨基喹唑啉衍生物的盐及其用途
ES2795666T3 (es) Una triazolopiridazina deuterada como un modulador de quinasa
WO2017218365A1 (en) Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
ES2632548T3 (es) Formas de estado sólido de los inhibidores de la quinasa macrocíclica
BR112021004546A2 (pt) formas cristalinas de um composto de quinazol e seus sais de cloridrato
CN106632253B (zh) 一种取代的喹啉化合物的晶型及其药物组合物和用途
CN106632254B (zh) 一种取代的喹啉化合物的晶型及其药物组合物和用途
CN109867671B (zh) 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
EP3727379B1 (en) Crystalline mono-sodium salt of n-(5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)2-methoxypyridin-3-yl)-2,4-difluoro-benzenesulfonamide
US20250230173A1 (en) Salt forms of an axl inhibitor
CN109867669A (zh) 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867672B (zh) 吡唑[1,5-a]吡啶衍生物的盐及其用途
CN109867670B (zh) 一种吡唑[1,5-a]吡啶化合物的单钠盐及其医药用途
CN109867668A (zh) 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途